Trimer IgG and neutralising antibody response to COVID-19 mRNA vaccination in individuals with sarcoidosis
Background Individuals with sarcoidosis are at higher risk for infection owing to underlying disease pathogenesis and need for immunosuppressive treatment. Current knowledge as to how subjects with sarcoidosis respond to different forms of vaccination is limited. We examined quantitative and functio...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2023-01-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/9/1/00025-2022.full |
| _version_ | 1797809438487216128 |
|---|---|
| author | Christen L. Vagts Yi-Shin Chang Christian Ascoli Jessica M. Lee Kai Huang Yue Huang Ruth A. Cherian Nandini Sarup Samantha R. Warpecha Russell Edafetanure-Ibeh Md-Ruhul Amin Tasmin Sultana Mahmood Ghassemi Nadera J. Sweiss Richard Novak David L. Perkins Patricia W. Finn |
| author_facet | Christen L. Vagts Yi-Shin Chang Christian Ascoli Jessica M. Lee Kai Huang Yue Huang Ruth A. Cherian Nandini Sarup Samantha R. Warpecha Russell Edafetanure-Ibeh Md-Ruhul Amin Tasmin Sultana Mahmood Ghassemi Nadera J. Sweiss Richard Novak David L. Perkins Patricia W. Finn |
| author_sort | Christen L. Vagts |
| collection | DOAJ |
| description | Background
Individuals with sarcoidosis are at higher risk for infection owing to underlying disease pathogenesis and need for immunosuppressive treatment. Current knowledge as to how subjects with sarcoidosis respond to different forms of vaccination is limited. We examined quantitative and functional antibody response to COVID-19 vaccination in infection-naive subjects with and without sarcoidosis.
Methods
Our prospective cohort study recruited 14 subjects with biopsy-proven sarcoidosis and 27 age–sex matched controls who underwent a two-shot series of the BNT162b2 mRNA vaccine at the University of Illinois at Chicago. Baseline, 4-week and 6-month trimer spike protein IgG and neutralising antibody (nAb) titres were assessed. Correlation and multivariate regression analysis was conducted.
Results
Sarcoidosis subjects had a significant increase in short-term antibody production to a level comparable to controls; however, IgG titres significantly declined back to baseline levels by 6 months. Corresponding neutralising assays revealed robust nAb titres in sarcoidosis subjects that persisted at 6 months. A significant and strong correlation between IgG and nAb titres across all time points was observed in the control group. However within the sarcoidosis group, a significant but weak correlation between antibody levels was found. Overall, IgG levels were poor predictors of nAb titres at short- or long-term time points.
Conclusions
Sarcoidosis subjects exhibit nAb induced by the BNT162b2 mRNA SARS-CoV-2 vaccine at levels comparable to controls that persists at 6 months indicating conferred immunity. Trimer IgG levels are poor predictors of nAb in subjects with sarcoidosis. Studies of further antibody immunoglobulins and subtypes warrant investigation. |
| first_indexed | 2024-03-13T06:52:47Z |
| format | Article |
| id | doaj.art-79fbfa4e161445099a271d51a0e70983 |
| institution | Directory Open Access Journal |
| issn | 2312-0541 |
| language | English |
| last_indexed | 2024-03-13T06:52:47Z |
| publishDate | 2023-01-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | ERJ Open Research |
| spelling | doaj.art-79fbfa4e161445099a271d51a0e709832023-06-07T13:30:43ZengEuropean Respiratory SocietyERJ Open Research2312-05412023-01-019110.1183/23120541.00025-202200025-2022Trimer IgG and neutralising antibody response to COVID-19 mRNA vaccination in individuals with sarcoidosisChristen L. Vagts0Yi-Shin Chang1Christian Ascoli2Jessica M. Lee3Kai Huang4Yue Huang5Ruth A. Cherian6Nandini Sarup7Samantha R. Warpecha8Russell Edafetanure-Ibeh9Md-Ruhul Amin10Tasmin Sultana11Mahmood Ghassemi12Nadera J. Sweiss13Richard Novak14David L. Perkins15Patricia W. Finn16 Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Background Individuals with sarcoidosis are at higher risk for infection owing to underlying disease pathogenesis and need for immunosuppressive treatment. Current knowledge as to how subjects with sarcoidosis respond to different forms of vaccination is limited. We examined quantitative and functional antibody response to COVID-19 vaccination in infection-naive subjects with and without sarcoidosis. Methods Our prospective cohort study recruited 14 subjects with biopsy-proven sarcoidosis and 27 age–sex matched controls who underwent a two-shot series of the BNT162b2 mRNA vaccine at the University of Illinois at Chicago. Baseline, 4-week and 6-month trimer spike protein IgG and neutralising antibody (nAb) titres were assessed. Correlation and multivariate regression analysis was conducted. Results Sarcoidosis subjects had a significant increase in short-term antibody production to a level comparable to controls; however, IgG titres significantly declined back to baseline levels by 6 months. Corresponding neutralising assays revealed robust nAb titres in sarcoidosis subjects that persisted at 6 months. A significant and strong correlation between IgG and nAb titres across all time points was observed in the control group. However within the sarcoidosis group, a significant but weak correlation between antibody levels was found. Overall, IgG levels were poor predictors of nAb titres at short- or long-term time points. Conclusions Sarcoidosis subjects exhibit nAb induced by the BNT162b2 mRNA SARS-CoV-2 vaccine at levels comparable to controls that persists at 6 months indicating conferred immunity. Trimer IgG levels are poor predictors of nAb in subjects with sarcoidosis. Studies of further antibody immunoglobulins and subtypes warrant investigation.http://openres.ersjournals.com/content/9/1/00025-2022.full |
| spellingShingle | Christen L. Vagts Yi-Shin Chang Christian Ascoli Jessica M. Lee Kai Huang Yue Huang Ruth A. Cherian Nandini Sarup Samantha R. Warpecha Russell Edafetanure-Ibeh Md-Ruhul Amin Tasmin Sultana Mahmood Ghassemi Nadera J. Sweiss Richard Novak David L. Perkins Patricia W. Finn Trimer IgG and neutralising antibody response to COVID-19 mRNA vaccination in individuals with sarcoidosis ERJ Open Research |
| title | Trimer IgG and neutralising antibody response to COVID-19 mRNA vaccination in individuals with sarcoidosis |
| title_full | Trimer IgG and neutralising antibody response to COVID-19 mRNA vaccination in individuals with sarcoidosis |
| title_fullStr | Trimer IgG and neutralising antibody response to COVID-19 mRNA vaccination in individuals with sarcoidosis |
| title_full_unstemmed | Trimer IgG and neutralising antibody response to COVID-19 mRNA vaccination in individuals with sarcoidosis |
| title_short | Trimer IgG and neutralising antibody response to COVID-19 mRNA vaccination in individuals with sarcoidosis |
| title_sort | trimer igg and neutralising antibody response to covid 19 mrna vaccination in individuals with sarcoidosis |
| url | http://openres.ersjournals.com/content/9/1/00025-2022.full |
| work_keys_str_mv | AT christenlvagts trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT yishinchang trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT christianascoli trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT jessicamlee trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT kaihuang trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT yuehuang trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT ruthacherian trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT nandinisarup trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT samantharwarpecha trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT russelledafetanureibeh trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT mdruhulamin trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT tasminsultana trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT mahmoodghassemi trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT naderajsweiss trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT richardnovak trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT davidlperkins trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis AT patriciawfinn trimeriggandneutralisingantibodyresponsetocovid19mrnavaccinationinindividualswithsarcoidosis |